Number needed to treat (NNT) as a drug efficacy measure: Zoledronic acid (ZOL) for early hormone-responsive breast cancer in the ABCSG-12 trial

Gnant, M, Mlineritsch, B, Schippinger, W, Luschin-Ebengreuth, G, Steger, G, Bjelic-Radisic, V, Jakesz, R, Kubista, E, Marth, C, Greil, R BREAST. 2009, 18: S59-S59.

The number needed to treat (NNT) as a measure of drug efficacy: the case of zoledronic acid for early hormone-responsive breast cancer in the ABCSG-12 trial

Gnant, M, Mlineritsch, B, Schippinger, W, Luschin-Ebengreuth, G, Steger, G, Bjelic-Radisic, V, Jakesz, R, Kubista, E, Marth, C, Greil, R CANCER RES. 2009, 69(2): 191S-191S.

Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial.

Goetz, M, Ames, M, Gnant, M, Filpits, M, Jakesz, R, Greil, R, Marth, C, Samonigg, H, Suman, V, Safgren, S, Kuffel, M, Weinshilboum, R, Erlander, M, Ma, XJ, Ingle, J CANCER RES. 2009, 69(2): 77S-77S.

Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial

Lang, I, Inbar, M, Steger, G, Greil, R, Zvirbule, Z, Beslija, S, Kahan, Z, Taskova, V, Kaufmann, B, Zielinski, CC EJC SUPPL. 2009, 7(2): 277-278.

NUMBER NEEDED TO TREAT (NNT) AS A MEASURE OF ZOLEDRONIC ACID (ZOL) EFFICACY IN PATIENTS WITH HORMONE-RESPONSIVE EARLY BREAST CANCER (BC) IN THE AUSTRIAN BREAST AND COLORECTAL CANCER STUDY GROUP (ABCSG)-12 TRIAL

Gnant, M, Mlineritsch, B, Schippinger, W, Luschin-Ebengreuth, G, Steger, GG, Bjelic-Radisic, V, Jakesz, R, Kubista, E, Marth, C, Greil, R ANN ONCOL. 2009, 20: 30-30.

A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer – first results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24)

Steger, GG, Greil, R, Jakesz, R, Lang, A, Mlineritsch, B, Melbinger-Zeinitzer, E, Martin, C, Samonigg, H, Kubista, E, Gnant, M EJC SUPPL. 2009, 7(3): 3-3.

REVERSAL OF ACUTE RENAL IMPAIRMENT BY BORTEZOMIB-DOXORUBICIN-DEXAMETHASONE IN MULTIPLE MYELOMA. RESULTS FROM AN PHASE II STUDY

Ludwig, H, Adam, Z, Greil, R, Tothova, E, Keil, F, Zojer, N, Thaler, J, Gisslinger, H, Egyed, M, Lang, A HAEMATOL-HEMATOL J. 2009, 94: 154-154.

The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells.

Nevo I, Sagi-Assif O, Meshel T, Ben-Baruch A, Jöhrer K, Greil R, Trejo LE, Kharenko O, Feinmesser M, Yron I, Witz IP. Cancer Lett. 2009 Jan 8,273(1):127-39. doi: 10.1016/j.canlet.2008.07.029. Epub 2008 Sep 7.

Hodgkin lymphoma in Tyrol-a population-based study.

Fong D, Steurer M, Greil R, Gunsilius E, Spizzo G, Gastl G, Tzankov A. Ann Hematol. 2009 May,88(5):449-56. doi: 10.1007/s00277-008-0618-1. Epub 2008 Oct 10.

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.

Ludwig H, Hajek R, TГіthovГЎ E, Drach J, Adam Z, Labar B, Egyed M, Spicka I, Gisslinger H, Greil R, Kuhn I, Zojer N, Hinke A. Blood. 2009 Apr 9,113(15):3435-42. doi: 10.1182/blood-2008-07-169565. Epub 2008 Oct 27.